立体定向放疗联合化疗治疗中央型局部晚期非小细胞肺癌的疗效分析

目的:探讨使用射波刀行立体定向放疗（stereotactic body radiotherapy,SBRT）联合化疗治疗中央型局部晚期非小细胞肺癌（locally advanced non-small cell lung cancer,LA-NSCLC）的疗效和不良反应，评估射波刀的安全性和有效性，并进一步探索最佳的联合治疗方案。方法:回顾性分析了从2013年1月至2018年12月在我科接受射波刀联合化疗的中央型LA-NSCLC患者的临床病理特征，统计分析采用Kaplan-Meier检验和Cox多元回归模型。结果:共有59例患者纳入本研究，患者3年总生存率（overall survival,OS）、局部控制率（local control,LC）分别为25.4%和20.3%。与BED≤80 Gy组相比，BED>80 Gy组患者LC明显更好（P=0.008）且OS有延长的趋势（P=0.083）。≥3级放疗相关不良反应的发生率为13.6%。结论:射波刀联合化疗治疗中央型LA-NSCLC有效且不良反应可耐受。

Efficacy of stereotactic body radiotherapy combined with chemotherapy in the treatment of central locally advanced non-small cell lung cancer

Objective:To investigate the efficacy and adverse reactions of Cyberknife stereotactic body radiotherapy combined with chemotherapy in the treatment of central locally advanced non-small cell lung cancer.Methods:We retrospectively reviewed the clinicopathological characteristics of patients with central LA-NSCLC who received Cyberknife combined with chemotherapy in our department from January 2013 to December 2018.Kaplan-Meier test and Cox multivariate regression model wereused for analysis.Results:A total of 59 patients were included in this study,and the 3-year overall survival (OS),local control (LC) were 25.4%and 20.3%.Compared with patients of BED≤80 Gy group,BED>80 Gy group patients had a statistically significant difference in LC(P=0.008),and they did have a trend towards better OS (P=0.083).The incidence of grade≥3 radiation-related adverse reactions was 13.6%.Conclusion:Our evaluation results indicated that Cyberknife combined with chemotherapy in the treatment of central LA-NSCLC was effective and the adverse reactions can be tolerated.